SABR: Prescription dose/fractionation: 26Gy/5 with 40Gy/5 +/- 35Gy/5 Boost Radiation Technique: VMAT Treatment Frequency: Every other day (EOD)
Study summary
The study is being done to determine if stereotactic ablative radiotherapy (SABR) can control tumour growth for patients with metastatic breast cancer.
Secondary objectives will be overall survival, progression-free survival and time to switch of next line of systemic therapy.
Radiation-related adverse events will be assess, with a specific focus on dermatitis, lymphedema and brachial plexopathy.
The exploratory objective is to correlate toxicities and outcomes with peripheral blood biomarkers and circulating tumor DNA to potentially help predict responses in future patients receiving combined therapy.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Pathologically confirmed AJCC 7th/8th edition Stage IV invasive ductal carcinoma or invasive lobular carcinoma of the breast.
2. Measurable disease in the breast, suitable to receive radiotherapy.
3. Receiving or planned to receive systemic therapy.
a. The following should be held for the duration of treatment: cytotoxic chemotherapy, CDK4/6 inhibitors, T-DXd
4. Patients are allowed to have SABR for oligometastatic disease as clinically indicated
5. Age 18 or older
6. ECOG Performance Status 0-2
7. Life expectancy greater than 6 months
8. Able and willing to provide informed consent
9. Able to complete patient reported outcome questionnaires
Exclusion Criteria:
1. Contraindications to radiotherapy, including a history of SLE, systemic scleroderma, IPF, ataxia telangiectasia, pregnancy
2. Previous history of locoregional radiotherapy to the ipsilateral breast
Primary outcome measure(s)
Locoregional Control — 2 Years Assess median, 1-year and 2-year locoregional control
Trial sites (1)
Facility
City
Region
Status
BC Cancer - Vancouver
Vancouver
British Columbia
More British Columbia Cancer Agency trials in Canada
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.